Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

2012; Massachusetts Medical Society; Volume: 367; Issue: 16 Linguagem: Inglês

10.1056/nejmoa1203572

ISSN

1533-4406

Autores

William J. Sandborn, Christopher Gasink, Long-Long Gao, Marion Blank, Jewel Johanns, Cynthia Guzzo, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Paul Rutgeerts, Subrata Ghosh, Willem J.S. de Villiers, Remo Panaccione, Gordon R. Greenberg, Stefan Schreiber, Simon Lichtiger, Brian G. Feagan,

Tópico(s)

Autoimmune and Inflammatory Disorders

Resumo

In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.

Referência(s)